Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.
1. PFE and White House settle drug-pricing deal, boosting biotech stocks significantly. 2. Biotech sector showing signs of recovery after years of underperformance. 3. M&A activity is likely as Big Pharma faces patent expirations. 4. Investor sentiment cautious but improving due to potential profit growth in biotech. 5. Structural issues in the sector may be easing, leading to increased investment.